The Breast Journal / 2023 / Article / Tab 1 / Research Article
Hormonal-Receptors-Positive and HER2-Negative Patients with Metastatic Breast Cancer Treated with First-Line Palbociclib and Hormonal Therapy: Impact of First-Cycle Neutropenia and Dose Reduction on Therapeutic Outcome Table 1 Baseline clinicopathological factors and relation to neutropenia after 1st cycle.
Parameters Neutropenia Total P valueNo Yes ECOG PS 0 0 2 2 0.82 0.0% 100.0% 100.0% 1 15 94 109 13.8% 86.2% 100.0% 2 6 33 39 15.4% 84.6% 100.0% BMI Normal 2 21 23 0.71 8.7% 91.3% 100.0% Overweight 7 37 44 15.9% 84.1% 100.0% Obese 12 71 83 14.5% 85.5% 100.0% Ki67 level Low 15 71 86 0.02 17.4% 82.6% 100.0% High 4 56 60 6.7% 93.3% 100.0% NA 2 2 4 50.0% 50.0% 100.0% Menopausal status Premenopause 8 70 78 0.17 10.3% 89.7% 100.0% Postmenopause 13 59 72 18.1% 81.9% 100.0% Low HER2 expression No 10 73 83 0.44 12.0% 88.0% 100.0% Yes 11 56 67 16.4% 83.6% 100.0% Stage at diagnosis Stage II 1 3 4 0.68 25.0% 75.0% 100.0% Stage III 8 42 50 16.0% 84.0% 100.0% Stage IV 12 84 96 12.5% 87.5% 100.0% N -stageN x3 1 4 0.008 75.0% 25.0% 100.0% N 020 70 90 22.2% 77.8% 100.0% N 15 59 64 7.8% 92.2% 100.0% N 24 30 34 11.8% 88.2% 100.0% N 32 9 11 18.2% 81.8% 100.0% (Neo) adjuvant chemotherapy No 17 111 128 0.48 13.3% 86.7% 100.0% Yes 4 17 21 19.0% 81.0% 100.0% PR-status Negative 4 19 23 0.61 17.4% 82.6% 100.0% Positive 17 110 127 13.4% 86.6% 100.0% Site of metastasis Bone-only 5 27 32 0.76 15.6% 84.4% 100.0% Others 16 102 118 13.6% 86.4% 100.0% Site of metastasis Single 8 46 54 0.83 14.8% 85.2% 100.0% Multiple 13 83 96 13.5% 86.5% 100.0%